title: [Changes in the blood picture in hyperthyroidism].
abstract: On the basis of a retrospective study about 276 clinically and paraclinically ascertained cases of hyperthyroidism in 34% of the patients above all mild anaemias could be proved which under thyreostatic therapy with thiamazol which after repeated incidence of an euthyroid metabolic situation vastly normalized themselves also without an anaemia-specific additional medication. Leukocytopenias (5.8%) and thrombocytopenias (3.3%) had only a low frequency in untreated hyperthyroidism. Nevertheless an unequivocal parallelity of the haematologic changes was to be observed in erythro-, granulo- and thrombopoiesis. There was a clear correlation between the activity of hyperthyroidism, measured at the T3- or T4 level, and anaemia and haemocytopenia, respectively. Lacking substance deficiency conditions and signs of haemolysis let us first of all think of a causal thyrotoxic bone-marrow damage on account of the dependence of the haematologic changes on the activity of hyperthyroidism and their immediate influencibility by aimed thyrostatic therapy. A relatively low dosed thiamazol therapy has influence on haematopoiesis and peripheral blood picture only at a very small percentage, in which cases the changes mostly are fully reversible. Thereby the initial haematologic situation before the therapy does not provide any predictability for perhaps appearing haematotoxic or allergic side-effects under thyreostatic treatment. The thiamazol therapy does not show any recognizable side-effects in the dosage administered on the investigated leukocytic functions agglomeration, adhesion and phyagocytosis. Only for the adhesion of leukocytes was proved a significant functional disturbance of leukocytes, which was, however, reversible with normalization of metabolism and with high probability was also directly thyreotoxically induced.
authors.affiliation: Poliklinischen Abteilung Karl-Marx-Universität Leipzig.
authors.forename: K
authors.initials: K
authors.lastname: Hambsch
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
authors.forename: H
authors.initials: H
authors.lastname: Fischer
authors.forename: D
authors.initials: D
authors.lastname: Langpeter
authors.forename: P
authors.initials: P
authors.lastname: Mäller
authors.forename: D
authors.initials: D
authors.lastname: Sorger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000097:blood*; D000747:Anemia, Hypochromic / Q000097:blood*; D004906:Erythrocyte Count / Q000187:drug effects; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000097:blood*; D008134:Long-Term Care; D008297:Male; D008713:Methimazole / Q000008:administration & dosage; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D013921:Thrombocytopenia / Q000097:blood*; D013960:Thyroid Function Tests
chemical_list: D008713:Methimazole
vernacular_title: Blutbildveränderungen bei Hyperthyreose.